NEW YORK, Jan. 25, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ:GWPH) between December 4, 2014 and January 8, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/gw-pharmaceuticals.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/gw-pharmaceuticals.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 



